(NEW YORK) -- Ludlow Research updated its research opinion on MetAlert, Inc. (OTC: MLRT), a pioneer in location sensitive health monitoring devices and wearable technology products for remote patient monitoring, based on elimination of toxic debt and launch of new medical device products for cognitive markets.
Read recent Analyst Brief conducted Jan. 05, 2023
- Expansion of medical devices for aging and autism market
- Ramp-up in SmartSole unit production to fulfill backorders
- Elimination of toxic convertible debt
Toxic debt, or variable convertible notes, are a form of debt, which sometimes convert at deep discounts to market price, and are major contributors to shareholder dilution and price instability for small issuers.
In recent months, MetAlert extinguished all of their toxic convertible notes from their balance sheet, which should now provide increased stability to their public float.
The influx of new chips in Q4 2022 should significantly increase production of SmartSole units in early 2023. This ramp-up in production should help fulfill backorders currently in place, and increase revenues in the coming months.
The elimination of toxic debt, improved guidance to their NFC operations, and launch of new medical devices geared towards the geriatric and autism healthcare markets now places the company in a much healthier position going forward into 2023.
MetAlert, Inc. (OTC: MLRT) is a pioneer in smart, mobile, and wearable tracking and recovery location-based solutions, supported through a proprietary iot enterprise monitoring platform and intellectual property portfolio. The Company offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications, utilizing the latest in miniaturized, low power consumption GPS, Cellular, RF, NFC, and BLE technology, enabling subscribers to track in real time the whereabouts of people or high value assets. Known for its game-changing and award-winning patented GPS SmartSole – think Dr. Scholl’s meets LoJack, the world’s first visible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. MetAlert´s business model is built around technology innovation and the Company holds dozens of patents, with many issued patents in the area of GPS tracking. The Company has international distributors servicing customers across the globe with subscribers in over 40 countries, and is a U.S. Military Government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. www.MetAlert.com